|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||80.79 - 81.87|
|52 Week Range||58.66 - 88.98|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Investors have cooled on biotechnology stocks, taking some money off the table after enjoying a greater than 25% gain year-to-date through the end of September. Biotech mutual funds and exchange-traded ...
Don't judge an exchange-traded fund by its cover -- obvious advice, but apparently not obvious enough. The SPDR S&P Biotech ETF (XBI) has returned 42% so far this year, more than double that of the iShares ...
Biotechnology stocks and ETFs are slumping in the fourth quarter. For example, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR ...
Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.
Biotechnology fund outflows persist. For the week ended Nov. 29, biotechnology mutual funds and exchange-traded funds saw outflows of some $329 million, according to Lipper/AMG Data Services, which tracks ...
Biotech stocks have been a political football for over a year. Biogen Inc (NASDAQ:BIIB) stock managed to still be up almost 10% year-to-date. While BIIB stock has a high face value of $310 per share, it is not expensive.
It can be tricky putting a price tag on a biotech company, especially one that offers no profits but promises of big success one day in the future. Just because someone wearing a lab coat makes a breakthrough, doesn’t necessarily mean a blockbuster drug is on the horizon. Years can pass before it’s clear whether an experimental treatment will generate returns for a drug maker.
Investors appear to be hitting the snooze button on biotechnology stocks. Net flows are slowing after seeing two consecutive weeks of fresh money. Biotech fund flows, including mutual funds and exchange-traded funds, were essentially flat for the week ended Nov. 15.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) tumbled on Tuesday, extending losses that have ...
Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.
The latest Republican tax reform bill takes yet another stab at the Affordable Care Act with a proposed repeal of individual mandates, party leadership said Tuesday . The mandates had required Americans ...
Fresh money marched into biotechnology stock mutual funds and exchange-traded funds for the week ended Nov. 8, the second consecutive week of net inflows in the past six weeks, according to Lipper/AMG data. About $62 million flowed into 100 funds with some $58.7 billion in assets collectively. Flows are critical to biotech stock strength, according to Raymond James analyst Laura Chico. "In our view, biotech strength will likely be driven in part by specialist funds," she said in note published Thursday.
To say that Allergan Plc Ordinary Shares (NYSE:AGN) has had a bad second half of the summer is an understatement. Coming into this earnings report, and since its last earnings report in July, the stock had fallen 30%. At these levels, something had to give for AGN stock.
Pfizer Inc. (NYSE:PFE) reported earnings this morning and PFE stock is down on the news. Pfizer beat on the bottom line and boosts guidance. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) has fallen 7% in about two weeks perhaps most influenced by combative remarks from President Trump vowing to continue fighting drug stocks and their management practices.
After Cancer-Cure Makers Make Great Takeover Stocks was published in the October 24th issue of Forbes, a number of readers asked if there was a safe way to invest in biotech. Forbes reader Alice Lane asked the questions that seem to be on many people's minds. Here are my answers.
Biotechnology stock funds, including the mutual and exchange-traded variety, suffered outflows of $382 million for the week ended Oct. 18. It's just a drop in the bucket given 101 funds have about $61 ...
Last night, Celgene Corporation (NASDAQ:CELG) released a headline that they canceled phase three for their potential solution to Crohn’s disease. The stock is now trading down 10%. This means that it would now be down 16% since early October.Source: Wikimedia (Modified)
President Donald Trump repeated rhetoric from early in his presidency about drug prices being "out of control" and drugmakers "getting away with murder" on Monday, but said nothing ...
Biotech's earnings season is right around the corner, and while some analysts may be bullish, Raymond James's Laura Chico writes that fund flows have taken a pause ahead of the reports. For the week ended October 11, biotech funds saw net outflows of $220 million, or a 0.36% decrease in assets, according to data from Lipper/AMG Data Services, which covers 100 funds and about $61 billion in assets. Chico writes that this is the first week of outflows for the sector since the start of September.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech ETF by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI), are up 29% and 49%, respectively, year-to-date. ...
Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.
With third-quarter earnings season upon us, Morgan Stanley’s Matthew Harrison and his team take a look at the biotech sector, writing that it will likely be a mixed bag for the group, but he's still bullish on several names. Harrison reiterated an Outperform rating on Alexion (ALXN), although he warns that he is below consensus on revenues.